MCID: FCL012
MIFTS: 50

Facial Paralysis malady

Category: Neuronal diseases

Aliases & Classifications for Facial Paralysis

About this section

Aliases & Descriptions for Facial Paralysis:

Name: Facial Paralysis 11 38 13 67
Facial Palsy 11 26 13
 
Bell Palsy 67

Classifications:



External Ids:

Disease Ontology11 DOID:13934
ICD1029 G51.0
MeSH38 D005158
NCIt44 C26769

Summaries for Facial Paralysis

About this section
MalaCards based summary: Facial Paralysis, also known as facial palsy, is related to heart disease and recurrent peripheral facial palsy, and has symptoms including hemifacial paralysis, facial palsy, lower motor neuron and facial palsy, upper motor neuron. An important gene associated with Facial Paralysis is TGFB1 (Transforming Growth Factor Beta 1), and among its related pathways is N-cadherin signaling events. The drugs scopolamine and scopolamine hydrobromide have been mentioned in the context of this disorder. Affiliated tissues include bone, brain and eye, and related mouse phenotypes are craniofacial and respiratory system.

Related Diseases for Facial Paralysis

About this section

Diseases related to Facial Paralysis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 128)
idRelated DiseaseScoreTop Affiliating Genes
1heart disease29.7CD40LG, KANTR
2recurrent peripheral facial palsy12.0
3congenital hereditary facial paralysis-variable hearing loss syndrome11.9
4facial palsy, familial recurrent peripheral11.9
5deafness, conductive stapedial, with ear malformation and facial palsy11.9
6anotia facial palsy cardiac defect11.8
7bell's palsy11.8
8melkersson-rosenthal syndrome11.2
9moebius syndrome11.2
10camurati-engelmann disease10.8
11facial paresis, hereditary congenital, 110.8
12pontine tegmental cap dysplasia10.7
13strawberry gallbladder10.5CD40LG, TGFB1
14renal hypertension10.5CD40LG, TGFB1
15loin pain hematuria syndrome10.5CD40LG, TGFB1
16sideroblastic anemia10.4GSN, TGFB1
17gynecomastia10.4NF2, TGFB1
18frontotemporal lobar degeneration with ubiquitin-positive inclusions10.4LRP5, TGFB1
19binocular vision disease10.3CD40LG, TGFB1
20retinal perforation10.3CD40LG, HOXB1, LIPN
21hodgkin's lymphoma, lymphocytic-histiocytic predominance10.3CD40LG, TGFB1
22retroperitoneal fibrosis10.2CD40LG, TGFB1
23lipodystrophy, familial partial, type 610.2LRP5, TGFB1
24esophagus melanoma10.1CD40LG, TGFB1
25otitis media10.1
26long bones of lower limb cancer10.1CADM1, LIPN, MTRNR2L5
27rickettsialpox10.1CD40LG, KANTR
28pompholyx10.1CD40LG, KANTR
29facial nerve neoplasm10.1CD40LG, KANTR
30bone fracture10.0
31brachial plexus neuropathy10.0CD40LG, KANTR
32rocky mountain spotted fever10.0CD40LG, KANTR
33gastric neuroendocrine neoplasm10.0KANTR, NF2
34lynch syndrome10.0CD40LG, KANTR
35maxillary sinusitis10.0ANKH, LRP5, TGFB1
36central nervous system germinoma10.0KANTR, NF2
37acoustic neuroma9.9
38ectropion9.9
39neuroma9.9
40herpes simplex9.9
41intestinal pseudo-obstruction9.9CD40LG, KANTR
42neurilemmoma of the fifth cranial nerve9.9KANTR, NF2
43parotitis9.9
44cholesteatoma9.9
45peritoneal benign neoplasm9.9KANTR, NF2
46oesophagostomiasis9.9CD40LG, KANTR
47van buchem disease, type 29.9ANKH, LRP5
48central nervous system germ cell tumor9.9KANTR, NF2
49lymphoma9.9
50ptosis9.9

Comorbidity relations with Facial Paralysis via Phenotypic Disease Network (PDN):


Acute CystitisAphasia
Exposure KeratitisHypertension, Essential
Ischemic Heart DiseaseMechanical Ectropion
Paralytic LagophthalmosSwallowing Disorders
Transient Cerebral IschemiaGeniculate Herpes Zoster
Parotid Gland Cancer

Graphical network of the top 20 diseases related to Facial Paralysis:



Diseases related to facial paralysis

Symptoms for Facial Paralysis

About this section

UMLS symptoms related to Facial Paralysis:


hemifacial paralysis, facial palsy, lower motor neuron, facial palsy, upper motor neuron, facial paresis, sciatica, oral manifestations, ophthalmoplegia, hemiplegia, back pain, headache, flaccid muscle tone, pain, seizures, syncope, tremor, chronic pain, muscle weakness, vertigo/dizziness, diaphragmatic paresis, unilateral facial paresis, generalized muscle weakness, sleeplessness

Drugs & Therapeutics for Facial Paralysis

About this section

Drugs for Facial Paralysis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 70)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Prednisoloneapproved, vet_approvedPhase 4, Phase 3115350-24-85755
Synonyms:
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
.DELTA.1-Cortisol
.DELTA.1-Dehydrocortisol
.DELTA.1-Dehydrohydrocortisone
.DELTA.1-Hydrocortisone
.delta.-Cortef
.delta.-Stab
1,2-Dehydrohydrocortisone
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1-Dehydrocortisol
1-Dehydrohydrocortisone
3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene
46656_FLUKA
46656_RIEDEL
50-24-8
58201-11-9
8056-11-9
AC-1773
AC1L1L2E
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
BPBio1_000164
BRD-K98039984-001-03-0
BRN 1354103
BSPBio_000148
Bio-0666
Bubbli-Pred
C07369
CCRIS 980
CHEBI:8378
CHEMBL131
CID5755
CO-Hydeltra
CPD000718761
Co-Hydeltra
Codelcortone
Cordrol
Cortalone
Cotogesic
Cotolone
D00472
D011239
DB00860
Decaprednil
Decortin H
Delcortol
Delta F
Delta(1)-dehydrohydrocortisone
Delta-Cortef
Delta-Cortef (TN)
Delta-Ef-Cortelan
Delta-Stab
Delta-stab
Deltacortenol
Deltacortril
Deltacortril Enteric
Deltahydrocortisone
Deltasolone
Deltisilone
Depo-Medrol
Derpo PD
Derpo Pd
Dexa-Cortidelt Hostacortin H
Dexa-Cortidelt hostacortin H
Di Adreson F
Di-Adreson F
Di-Adreson-F
Di-adreson F
DiAdresonF
Dicortol
Donisolone
Dydeltrone
EINECS 200-021-7
Eazolin D
Econopred
Econopred Plus
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
Fernisolone-P
Flamasone
HMS1568H10
HMS2090J05
HSDB 3385
Hostacortin H
Hydeltra
Hydeltra-Tba
Hydeltrasol
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
I-Pred
Inflamase Forte
Inflamase Mild
K 1557
Key-Pred
Klismacort
LMST02030179
LS-7669
Lentosone
Lite Pred
M-Predrol
 
MLS001304083
MLS002154250
MLS002207037
Medrol
Medrol Acetate
Metacortandralone
Methylprednisolone Acetate
Meti-Derm
Meticortelone
Metreton
MolPort-002-507-147
NCGC00179649-01
NSC 9120
NSC9120
NSC9900
Neo-Delta-Cortef
Nisolone
Nor-Pred T.B.A.
Ocu-Pred
Ocu-Pred Forte
Ophtho-Tate
Orapred
P0152_SIGMA
P0637
P6004_SIGMA
PRDL
PRED-G
Panafcortelone
Paracortol
Paracotol
Pediapred
Poly-Pred
Precortalon
Precortancyl
Precortilon
Precortisyl
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
Predisolone Sodium Phosphate
Predne-Dome
Prednelan
Predni-Dome
Prednicen
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
Prednisolone (JP15/USP/INN)
Prednisolone (anhydrous)
Prednisolone Acetate
Prednisolone Sodium Phosphate
Prednisolone Tebutate
Prednisolone [INN:BAN:JAN]
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
Prelone
Prenolone
Prestwick0_000274
Prestwick1_000274
Prestwick2_000274
Prestwick3_000274
Prestwick_404
Rolisone
S1737_Selleck
SAM002264639
SMR000718761
SPBio_002367
Scherisolon
Solone
Steran
Sterane
Sterolone
Supercortisol
UNII-9PHQ9Y1OLM
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-Hydrogen
Ultracortene-hydrogen
ZINC03833821
component of Ataraxoid
component of K-Predne-Dome
delta(1)-Cortisol
delta(1)-Dehydrocortisol
delta(1)-Dehydrohydrocortisone
delta(1)-Hydrocortisone
delta(sup 1)-Cortisol
delta(sup 1)-Dehydrocortisol
delta(sup 1)-Dehydrohydrocortisone
delta(sup 1)-Hydrocortisone
delta-dehydrocortisol
delta-dehydrohydrocortisone
delta-hydrocortisone
prednisolone
2
Methylprednisoloneapproved, vet_approvedPhase 4, Phase 3115383-43-26741
Synonyms:
(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
.DELTA.1-6.alpha.-Methylhydrocortisone
1-Dehydro-6alpha-methylhydrocortisone
1-dehydro-6alpha-Methylhydrocortisone
1-dehydro-6α-methylhydrocortisone
11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione
11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
121673-01-6
4-08-00-03498 (Beilstein Handbook Reference)
46436_FLUKA
46436_RIEDEL
570-35-4
6 Methylprednisolone
6-Methylprednisolone
6-alpha-Methylprednisolone
6.alpha.-Methylprednisolone
6923-42-8
6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
83-43-2
AC1L1N7A
Artisone-Wyeth
Artisone-wyeth
BPBio1_000174
BRD-K35240538-001-03-1
BRN 2340300
BSPBio_000158
Besonia
Bio-0658
CHEBI:6888
CHEMBL650
CID6741
CPD000058330
D00407
D008775
DB00959
Depo-Medrol (acetate)
Dopomedrol
EINECS 201-476-4
Esametone
Firmacort
HMS1568H20
HMS2090B13
HSDB 3127
LMST02030178
LS-118498
Lemod
M0639_SIGMA
M1665
MEPRDL
MLS000028541
MLS001148159
MLS002207191
Medesone
Medixon
Medlone 21
 
Medrate
Medrol
Medrol (TN)
Medrol Adt Pak
Medrol Dosepak
Medrol adt pak
Medrol dosepak
Medrol, Solu-Medrol, Medrone, Methylprednisolone
Medrone
Mesopren
Metastab
Methyleneprednisolone
Methylprednisolon
Methylprednisolone
Methylprednisolone (JP15/USP/INN)
Methylprednisolone [USAN:INN:BAN:JAN]
Methylprednisolone, 6-alpha
Methylprednisolonum
Methylprednisolonum [INN-Latin]
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [DCIT]
Metilprednisolone [Dcit]
Metipred
Metrisone
Metrocort
Metysolon
Moderin
MolPort-002-528-554
NCGC00022735-03
NCI60_001657
NSC-19987
NSC19987
Nirypan
Noretona
Predni N Tablinen
Prednol- L
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI)
Prestwick0_000279
Prestwick1_000279
Prestwick2_000279
Prestwick3_000279
Prestwick_622
Promacortine
Reactenol
S1733_Selleck
SAM002589984
SMR000058330
SPBio_002377
Sieropresol
Solomet
Summicort
Suprametil
U 7532
UNII-X4W7ZR7023
Urbason
Urbasone
Wyacort
ZINC03875560
delta(1)-6alpha-Methylhydrocortisone
delta(sup 1)-6-alpha-Methylhydrocortisone
methylprednisolone
methylprenisolone
3
AcetylcholineapprovedPhase 4, Phase 277651-84-3187
Synonyms:
ACh
Acetyl choline ion
Acetylcholine Chloride
Acetylcholine cation
 
Acetylcholinium: acetyl-Choline
Choline acetate
Choline acetate (ester)
O-Acetylcholine
acetylcholine chloride
4
Lidocaineapproved, vet_approvedPhase 41226137-58-63676
Synonyms:
.alpha.-(Diethylamino)-2,6-acetoxylidide
.alpha.-Diethylamino-2,6-dimethylacetanilide
.alpha.-Diethylaminoaceto-2,6-xylidide
.omega.-Diethylamino-2,6-dimethylacetanilide
137-58-6
2-(Diethylamino)-2',6'-acetoxylidide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide
2-Diethylamino-N-(2,6-dimethylphenyl)acetamide
4-12-00-02538 (Beilstein Handbook Reference)
6108-05-0 (MONOHYDROCHLORIDE MONOHYDRATE))
6108-05-0 (mono-hydrochloride, mono-hydrate)
73-78-9 (mono-hydrochloride)
AB00053581
AC-10282
AC1L1GGQ
AC1Q2Z7J
AKOS001026768
ARONIS23855
After Burn Double Strength Gel
After Burn Double Strength Spray
After Burn Gel
After Burn Spray
Alphacaine
Anestacon
Anestacon Jelly
BIDD:GT0342
BPBio1_000197
BRD-K52662033-001-02-6
BRD-K52662033-003-05-5
BRN 2215784
BSPBio_000179
BSPBio_001359
BSPBio_003004
Bio-0767
Bio1_000379
Bio1_000868
Bio1_001357
Bio2_000079
Bio2_000559
C07073
C14H22N2O
CAS-73-78-9
CDS1_000283
CHEBI:6456
CHEMBL79
CID3676
CPD000058189
Cappicaine
Cito optadren
Cuivasil
D00358
DB00281
Dalcaine
Dentipatch
Dentipatch (TN)
DermaFlex
Diethylaminoaceto-2,6-xylidide
Dilocaine
DivK1c_000174
DivK1c_001323
Duncaine
EINECS 205-302-8
ELA-Max
EMBOLEX
Emla
Emla Cream
Esracaine
FT-0082378
Gravocain
HMS1791D21
HMS1989D21
HMS2051C21
HMS2089E15
HMS548M19
HSDB 3350
I01-2704
IDI1_000174
IDI1_033829
Isicaina
Isicaine
Jetocaine
KBio1_000174
KBio2_000079
KBio2_001598
KBio2_002647
KBio2_004166
KBio2_005215
KBio2_006734
KBio3_000157
KBio3_000158
KBio3_002224
KBioGR_000079
KBioGR_000599
KBioSS_000079
KBioSS_001598
L-Caine
L0156
L1026_SIGMA
L7757_SIGMA
LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE)
LIDOPEN
LQZ
 
LS-805
Lanabiotic
Leostesin
Lida-Mantle
Lidocaina
Lidocaina [INN-Spanish]
Lidocaine (JP15/USP/INN)
Lidocaine (VAN)
Lidocaine Carbonate
Lidocaine Hydrocarbonate
Lidocaine Monohydrochloride
Lidocaine [USAN:INN:JAN]
Lidocainum
Lidocainum [INN-Latin]
Lidocaton
Lidoderm
Lidoject-1
Lidoject-2
Lignocaine
Lignocainum
Lingocaine
Lopac-L-5647
Lopac0_000669
MLS000069724
MLS000758263
MLS001074177
Maricaine
Maybridge1_002571
MolPort-001-783-478
N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide
N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide
NCGC00015611-01
NCGC00015611-02
NCGC00015611-03
NCGC00015611-04
NCGC00015611-14
NCGC00022176-05
NCGC00022176-06
NCGC00022176-07
NCGC00022176-08
NCGC00022176-09
NINDS_000174
NSC 40030
NSC40030
Norwood Sunburn Spray
Octocaine
Octocaine-100
Octocaine-50
Prestwick0_000050
Prestwick1_000050
Prestwick2_000050
Prestwick3_000050
Remicaine
Rocephin Kit
Rucaina
S1357_Selleck
SAM001247018
SMR000058189
SPBio_001525
SPBio_002100
STK552033
Solarcaine
Solarcaine aloe extra burn relief cream
Solcain
Spectrum2_001343
Spectrum3_001392
Spectrum4_000070
Spectrum5_001549
Spectrum_001118
UNII-98PI200987
WLN: 2N2 & 1VMR B1 F1
Xilina
Xilocaina
Xilocaina [Italian]
Xllina
Xycaine
Xylestesin
Xylesthesin
Xylocain
Xylocaine
Xylocaine (TN)
Xylocaine 5% Spinal
Xylocaine CO2
Xylocaine Dental Ointment
Xylocaine Endotracheal
Xylocaine Test Dose
Xylocaine Viscous
Xylocaine-MPF
Xylocaine-MPF with Glucose
Xylocaine-Mpf
Xylocaine-Mpf with Glucose
Xylocard
Xylocitin
Xyloneural (free base)
Xylotox
Zilactin-L
Zingo
alfa-Dietilamino-2,6-dimetilacetanilide
alfa-Dietilamino-2,6-dimetilacetanilide [Italian]
alpha-Diethylamino-2,6-dimethylacetanilide
alpha-diethylamino-2,6-dimethylacetanilide
lidocaine
nchembio.65-comp16
α-diethylamino-2,6-dimethylacetanilide
5Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 222776
6Methylprednisolone HemisuccinatePhase 4, Phase 31153
7Neuroprotective AgentsPhase 4, Phase 31672
8Prednisolone hemisuccinatePhase 4, Phase 31153
9Protective AgentsPhase 4, Phase 37190
10Prednisolone phosphatePhase 4, Phase 31153
11Prednisolone acetatePhase 4, Phase 31153
12Methylprednisolone acetatePhase 4, Phase 31153
13Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 312767
14Antineoplastic Agents, HormonalPhase 4, Phase 35407
15Anti-Inflammatory AgentsPhase 4, Phase 310355
16AntiemeticsPhase 4, Phase 33888
17Autonomic AgentsPhase 4, Phase 39774
18Gastrointestinal AgentsPhase 4, Phase 38109
19HormonesPhase 4, Phase 313979
20Hormone AntagonistsPhase 4, Phase 312778
21glucocorticoidsPhase 4, Phase 34920
22Neurotransmitter AgentsPhase 4, Phase 3, Phase 2, Phase 117734
23onabotulinumtoxinAPhase 4, Phase 2626
24AcyclovirPhase 4178
25incobotulinumtoxinAPhase 4, Phase 2635
26Anesthetics, LocalPhase 43272
27AnestheticsPhase 49001
28Central Nervous System DepressantsPhase 412806
29Cholinergic AgentsPhase 4, Phase 23846
30Antiviral AgentsPhase 49732
31valacyclovirPhase 4104
32VaccinesPhase 4, Phase 36428
33Botulinum Toxins, Type APhase 4, Phase 2630
34abobotulinumtoxinAPhase 4, Phase 2626
35Anti-Infective AgentsPhase 4, Phase 321402
36Sodium Channel BlockersPhase 41515
37Anti-Arrhythmia AgentsPhase 42969
38Diuretics, Potassium SparingPhase 41827
39
TenecteplaseapprovedPhase 3, Phase 240191588-94-0
Synonyms:
191588-94-0
D06070
Tenecteplase
Tenecteplase (USAN/INN)
 
Tissue-type plasminogen activator precursor
Tnkase
Tnkase (TN)
t- PA
t-plasminogen activator
tPA
40
Aspirinapproved, vet_approvedPhase 3111250-78-22244
Synonyms:
11126-35-5
11126-37-7
1oxr
2-(ACETYLOXY)benzoic acid
2-(Acetyloxy)benzoate
2-(Acetyloxy)benzoic acid
2-Acetoxybenzenecarboxylic acid
2-Acetoxybenzoate
2-Acetoxybenzoic acid
2-Carboxyphenyl acetate
2349-94-2
26914-13-6
50-78-2
8-hour Bayer
98201-60-6
A 5376
A.S.A
A.S.A.
A.S.A. Empirin
A.S.A. empirin
A2093_SIGMA
A3160_SIGMA
A5376_SIGMA
A6810_SIGMA
AB1003266
AC 5230
AC1L1D8U
AC1Q1LA0
ACETYLSALICYLIC ACID
AI3-02956
AIN
AKOS000118884
ASA
Acenterine
Acesal
Acetal
Acetard
Aceticyl
Acetilsalicilico
Acetilum acidulatum
Acetisal
Acetol
Acetonyl
Acetophen
Acetosal
Acetosalic acid
Acetosalin
Acetoxybenzoic acid
Acetylin
Acetylsal
Acetylsalicylate
Acetylsalicylic acid
Acetylsalicylsaeure
Acetylsalicylsaure
Acetylsalycilic acid
Acetyonyl
Acetysal
Acetysalicylic acid
Acide 2-(acetyloxy)benzoique
Acide acetylsalicylique
Acide acétylsalicylique
Acido O-acetil-benzoico
Acido acetilsalicilico
Acidum acetylsalicylicum
Acimetten
Acisal
Acylpyrin
Adiro
Aloxiprimum
Asacard
Asagran
Asatard
Ascoden-30
Aspalon
Aspec
Aspergum
Aspir-Mox
Aspirdrops
Aspirin
Aspirin (JP15/USP)
Aspirin [BAN:JAN]
Aspirina 03
Aspirine
Asprin
Aspro
Aspro Clear
Asteric
Azetylsalizylsaeure
Azetylsalizylsäure
BIDD:GT0118
BRN 0779271
Bay-e-4465
Bayer
Bayer Aspirin 8 Hour
Bayer Buffered
Bayer Extra Strength Aspirin For Migraine Pain
Bayer Plus
Benaspir
Bi-prin
Bialpirina
Bialpirinia
Bufferin
C01405
CCRIS 3243
CHEBI:15365
CHEMBL25
CID2244
Caprin
Cardioaspirin
Cardioaspirina
Cemirit
Claradin
Clariprin
Colfarit
Contrheuma retard
Coricidin
Crystar
D00109
D001241
DB00945
Decaten
Delgesic
Dispril
DivK1c_000555
Dolean pH 8
Duramax
ECM
EINECS 200-064-1
EU-0100038
Easprin
Easprin (TN)
Ecolen
Ecotrin
Empirin
Empirin with Codeine
Endosprin
Endydol
 
Entericin
Enterophen
Enterosarein
Enterosarine
Entrophen
Extren
Globentyl
Globoid
HMS1920E13
HMS2090G03
HMS2091K13
HMS501L17
HSDB 652
Helicon
I14-7505
IDI1_000555
Idragin
Istopirin
KBio1_000555
KBio2_001725
KBio2_002271
KBio2_004293
KBio2_004839
KBio2_006861
KBio2_007407
KBio3_002149
KBio3_002751
KBioGR_000398
KBioGR_002271
KBioSS_001725
KBioSS_002272
Kapsazal
Kyselina 2-acetoxybenzoova
Kyselina acetylsalicylova
LS-143
Levius
Lopac-A-5376
Lopac0_000038
MLS001055329
MLS001066332
MLS001336045
MLS001336046
Magnecyl
Measurin
Medisyl
Micristin
MolPort-000-871-622
NCGC00015067-01
NCGC00015067-04
NCGC00015067-09
NCGC00090977-01
NCGC00090977-02
NCGC00090977-03
NCGC00090977-04
NCGC00090977-05
NCGC00090977-06
NCGC00090977-07
NCI60_002222
NINDS_000555
NSC 27223
NSC27223
NSC406186
Neuronika
Novid
Nu-seals
Nu-seals aspirin
O-(Acetyloxy)benzoate
O-(Acetyloxy)benzoic acid
O-Acetoxybenzoate
O-Acetoxybenzoic acid
O-Acetylsalicylic acid
O-Carboxyphenyl acetate
O-accetylsalicylic acid
O-acetylsalicylic acid
PL-2200
Persistin
Pharmacin
Pirseal
Polopirin
Polopiryna
Premaspin
R16CO5Y76E [UNII]
Rheumin tabletten
Rheumintabletten
Rhodine
Rhonal
Ronal
S-211
SMR000059138
SP 189
SPBio_001838
SPECTRUM1500130
ST075414
Salacetin
Salcetogen
Saletin
Salicylic acid acetate
Salicylic acid, acetate
Salospir
Solfrin
Solprin
Solprin acid
Solpyron
Solupsan
Spectrum2_001899
Spectrum3_001295
Spectrum4_000099
Spectrum5_000740
Spectrum_001245
Spira-Dine
St. Joseph
St. Joseph Aspirin for Adults
Supac
Tasprin
Temperal
Toldex
Triaminicin
Triple-sal
UNII R16CO5Y76E
UNII-R16CO5Y76E
UNII=R16CO5Y76E
UNM-0000306102
Vanquish
WLN: QVR BOV1
XAXA
Xaxa
Yasta
ZORprin
aspirin
cMAP_000006
component of Midol
component of Synirin
nchem.859-comp6
o-Acetoxybenzoic acid
o-Carboxyphenyl acetate
o-acetoxybenzoic acid
o-carboxyphenyl acetate
ácido acetilsalicílico
41
Clopidogrelapproved, nutraceuticalPhase 3756120202-66-6, 113665-84-260606
Synonyms:
( )-(S)-Clopidogrel
(+)-(S)-Clopidogrel
(+)-Clopidogrel
(S)-Clopidogrel
(S)-Methyl 2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetate
113665-84-2
AC-19024
AC1L1TKZ
AC1Q41I9
BIDD:GT0284
BRD-K27721098-065-02-9
BSPBio_003211
C16H16ClNO2S
CGE
CHEBI:37941
CHEMBL1771
CID60606
CLOPIDOGREL SULFATE
CPD000550475
Clopidogrel
Clopidogrel (INN)
Clopidogrel (TN)
Clopidogrel [BAN:INN]
Clopidogrel [Ban:Inn]
Clopidogrel [INN:BAN]
Clopidogrel bisulfate
Clopidogrel bisulphate
Clopidogrel sulfate
Clopidogrelum
D07729
DB00758
DivK1c_000787
HMS2090O21
HMS502H09
HSDB 7430
IDI1_000787
 
Isocover
KBio1_000787
KBio2_000545
KBio2_003113
KBio2_005681
KBio3_002431
KBioGR_000689
KBioSS_000545
LS-172232
MLS001165708
MLS001195633
MLS001304711
Methyl (+)-(S)-alpha-(o-chlorophenyl)-6,7-dihydrothieno(3,2-c)pyridine-5(4H)-acetate
MolPort-002-885-817
MolPort-003-845-991
NCGC00163329-02
NINDS_000787
Plavix
Plavix (TN)
SAM002589956
SMR000550475
SPBio_000463
SR 25990
STK580572
STOCK5S-27782
Spectrum2_000512
Spectrum3_001606
Spectrum4_000175
Spectrum_000105
TL8000400
UNII-A74586SNO7
Zyllt
clopidogrel
clopidogrel, (+)(S)-isomer
methyl (2S)-(2-chlorophenyl)(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)ethanoate
methyl (2S)-2-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate
nchem.651-comp8
42Fibrinolytic AgentsPhase 3, Phase 22317
43Platelet Aggregation InhibitorsPhase 32419
44Tissue Plasminogen ActivatorPhase 3, Phase 2231
45PlasminogenPhase 3, Phase 2236
46Purinergic P2 Receptor AntagonistsPhase 3769
47Purinergic P2Y Receptor AntagonistsPhase 3767
48Plasminogen InactivatorsPhase 310
49
EthanolapprovedPhase 2204364-17-5702
Synonyms:
(C6-C9)Alkyl alcohol
02483_FLUKA
02851_FLUKA
02853_FLUKA
02854_FLUKA
02855_FLUKA
02856_FLUKA
02856_SIAL
02857_FLUKA
02857_SIAL
02858_FLUKA
02858_SIAL
02860_FLUKA
02865_FLUKA
02865_SIAL
02870_FLUKA
02870_SIAL
02875_FLUKA
02877_FLUKA
02878_FLUKA
02882_FLUKA
02882_SIAL
02883_FLUKA
02884_FLUKA
02890_FLUKA
02890_SIAL
02891_FLUKA
02891_SIAL
1-Hydroxyethane
100C.NPA
121182-78-3
187380_ALDRICH
187380_SIAL
24102_RIEDEL
24102_SIAL
24103_RIEDEL
24103_SIAL
24105_RIEDEL
24105_SIAL
24106_RIEDEL
24106_SIAL
24194_RIEDEL
24194_SIAL
245119_ALDRICH
245119_SIAL
270741_ALDRICH
270741_SIAL
277649_ALDRICH
277649_SIAL
2858_SIGMA
29221_FLUKA
32205_RIEDEL
32205_SIAL
32221_RIEDEL
32221_SIAL
32294_RIEDEL
32294_SIAL
34870_SIAL
34963_RIEDEL
39278_FLUKA
40210_ALDRICH
40210_RIEDEL
41322_FLUKA
458600_ALDRICH
458600_SIAL
459828_ALDRICH
459828_SIAL
459836_ALDRICH
459836_SIAL
459844_SIAL
48075_SUPELCO
493511_SIAL
493538_ALDRICH
493538_SIAL
493546_ALDRICH
493546_SIAL
64-17-5
676829_SIAL
68475-56-9
71076-86-3
71329-38-9
8000-16-6
8024-45-1
AC1L19TW
AC1Q31MM
AHD 2000
AI3-01706
ALCOHOL 5% IN D5-W
Absolute Alcohol
Absolute Ethanol
Absolute alcohol
Absolute ethanol
Absolute ethyl alcohol
Aethanol
Aethanol [German]
Aethylalkohol
Alcare Hand Degermer
Alcohol
Alcohol (USP)
Alcohol (ethyl)
Alcohol Anhydrous
Alcohol [USP]
Alcohol anhydrous
Alcohol dehydrated
Alcohol denatured
Alcohol etílico
Alcohol, Absolute
Alcohol, Dehydrated
Alcohol, Diluted
Alcohol, Grain
Alcohol, anhydrous
Alcohol, dehydrated
Alcohol, denatured
Alcohol, diluted
Alcohol, ethyl
Alcohols
Alcohols, C1-3
Alcohols, C30
Alcohols, C6-9
Alcool Ethylique
Alcool Etilico
Alcool ethylique
Alcool etilico
Alcool éthylique
Algrain
Alkohol
Alkohol [German]
Alkoholu Etylowego
Alkoholu etylowego
Aminoethanol
Anhydrol
Anhydrol PM 4085
Anhydrous alcohol
Anhydrous ethanol
Beta-Aminoethanol
Beta-Aminoethyl Alcohol
Beta-Ethanolamine
Beta-Hydroxyethylamine
C00469
C2H5OH
C2H6O
CCRIS 945
CDA 19
CDA 19-200
CHEBI:16236
CHEMBL545
CID702
Caswell No. 426
Caswell No. 430
Colamine
Cologne Spirit
Cologne spirit
Cologne spirits
 
D000431
D00068
DB00898
Dehydrated Ethanol
Dehydrated alcohol
Dehydrated ethanol
Denatured Alcohol
Denatured Alcohol Cd-10
Denatured Alcohol Cd-5
Denatured Alcohol Cd-5a
Denatured Alcohol Sd-1
Denatured Alcohol Sd-13a
Denatured Alcohol Sd-17
Denatured Alcohol Sd-23a
Denatured Alcohol Sd-28
Denatured Alcohol Sd-30
Denatured Alcohol Sd-39b
Denatured Alcohol Sd-39c
Denatured Alcohol Sd-3a
Denatured Alcohol Sd-40m
Denatured Ethanol
Denatured alcohol
Denatured ethanol
Desinfektol EL
Diluted Alcohol
Distilled spirits
E2385_SIGMA
E7023_ALDRICH
E7023_SIAL
E7148_ALDRICH
E7148_SIAL
E7517_SIGMA
EINECS 200-578-6
EINECS 270-649-4
EOH
EOX
ETA
Envision Conditioner Pdd 9020
Esumiru WK 88
EtOH
Etanolo
Etanolo [Italian]
Ethanol (9CI)
Ethanol 200 Proof
Ethanol 200 proof
Ethanol Absolute
Ethanol Absolute Bp
Ethanol Anhydrous
Ethanol Extra Pure
Ethanol Vapor
Ethanol [JAN]
Ethanol solution
Ethanol, Silent Spirit
Ethanol, undenatured
Ethanolum anhydricum
Ethicap
Ethyl Alcohol
Ethyl Alcohol & Water, 10%
Ethyl Alcohol & Water, 20%
Ethyl Alcohol & Water, 30%
Ethyl Alcohol & Water, 40%
Ethyl Alcohol & Water, 5%
Ethyl Alcohol & Water, 50%
Ethyl Alcohol & Water, 60%
Ethyl Alcohol & Water, 70%
Ethyl Alcohol & Water, 80%
Ethyl Alcohol & Water, 95%
Ethyl Alcohol & Water, 96%
Ethyl Alcohol Anhydrous
Ethyl Alcohol, Anhydrous
Ethyl Alcohol, Denatured
Ethyl Hydrate
Ethyl Hydroxide
Ethyl alc
Ethyl alcohol
Ethyl alcohol anhydrous
Ethyl alcohol in alcoholic beverages
Ethyl alcohol usp
Ethyl hydrate
Ethyl hydroxide
Ethylalcohol
Ethylalcohol [Dutch]
Ethylol
Ethylolamine
Ethyloxy Group
Etylowy alkohol
FEMA No. 2419
FEMA Number 2419
Fermentation alcohol
Glycinol
Grain alcohol
HSDB 531
HSDB 82
HYDROXYETHYL GROUP
Hinetoless
Hydroxyethane
I14-12648
IMS 99
Infinity Pure
Jaysol
Jaysol S
LS-1539
LTBB002977
Lux
Methylated Spirit Mineralised
Methylated spirit
Methylcarbinol
MolPort-001-785-844
Molasses alcohol
NCGC00091458-01
NCI-C03134
NSC 85228
NSC85228
Oxydimethylene Group
Potato alcohol
Punctilious ethyl alcohol
Pyro
QMHAIh@
Reagent Alcohol
Ru-Tuss Expectorant
SDA 3A
SDA 40-2
SDM No. 37
SY Fresh M
Sekundasprit
Silent spirit
Spirit
Spirits of wine
Spiritus vini
Spirt
Synasol
Tecsol
Tecsol C
Thanol
Thiofaco M-50
UNII-3K9958V90M
USAF EK-1597
Undenatured Ethanol
WLN: Q2
absolute alcohol
alcohol
alcohol etilico
bmse000297
etanol
ethanol
ethyl alcohol
grain alcohol
nchem.651-comp3c
nchembio.552-comp10
nchembio.94-comp20
spiritus vini
Äthanol
Äthylalkohol
éthanol
50
Carbon monoxideapprovedPhase 2, Phase 1116630-08-0281
Synonyms:
CO
 
Carbon monoxide
Carboneum oxygenisatum
carbon(II) oxide

Interventional clinical trials:

(show top 50)    (show all 59)
idNameStatusNCT IDPhase
1Scandinavian Bell's Palsy StudyCompletedNCT00510263Phase 4
2Postmarketing Safety Study of Q/LAIV in Subjects 2 Through 49 Years of AgeCompletedNCT01985997Phase 4
3Post Marketing Surveillance Study of DysportCompletedNCT00210431Phase 4
4Reinnervation of Facial Muscles After Lengthening Temporalis MyoplastyTerminatedNCT01833221Phase 4
5Corticosteroids in Prevention of Facial Palsy After Cranial Base SurgeryCompletedNCT00438087Phase 3
6Additional 6-Month Safety Follow-up After Completion of Precursor Study 880801CompletedNCT01604746Phase 3
7A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven OcclusionRecruitingNCT02398656Phase 3
8Quadrant Versus Superficial ParotidectomyWithdrawnNCT01607866Phase 2, Phase 3
9Comparison of Antibiotic Therapy Alone or Combined With Corticosteroids for the Treatment of Nontuberculous Mycobacterial Cervicofacial Lymphadenitis in Children: A Randomized Double-Blind Placebo-Controlled StudyWithdrawnNCT01614977Phase 3
10Finding of Optimal Dose for NT 201 in the Treatment of Glabellar Frown LinesCompletedNCT00430586Phase 2
11TNK-tPA Evaluation for Minor Ischemic Stroke With Proven OcclusionCompletedNCT01654445Phase 2
12Botulinum Toxin A for Emotional Stabilization in Borderline Personality Disorder (BPD)RecruitingNCT02728778Phase 2
13Treatment of Temporo-Myofascial Disorder of Muscular Origin Using Botulinum Toxin: A Prospective StudyNot yet recruitingNCT02810015Phase 2
14Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velocardiofacial SyndromeTerminatedNCT01127503Phase 2
15Study of Inhaling Carbon Monoxide to Treat Patients With Intestinal Paralysis After Colon Surgery.TerminatedNCT01050712Phase 2
16Safety Study of Inhaling Carbon Monoxide in Healthy VolunteersTerminatedNCT01050933Phase 1
17The Relationship Between Psychological Factors and Bell's PalsyUnknown statusNCT01377766
18Prednisone and Acupuncture for the Treatment of Facial Neuritis: a Multiple Center, CER in ChinaUnknown statusNCT01201642
19ePrime: Evaluation of Magnetic Resonance (MR) Imaging to Predict Neurodevelopmental Impairment in Preterm InfantsUnknown statusNCT01049594
20Anthropometric Angular Measurement to Determine Muscle Tonus in Patients With Peripheral Facial ParalysisCompletedNCT00903669
21Microbiologic Findings of Acute Facial Palsy in ChildrenCompletedNCT01537952
22Myofunctional Therapy in Facial PalsyCompletedNCT00989209
23Steroid-Antiviral Treatment in Rehabilitation of Facial PalsyCompletedNCT02328079
24Assessment of the Cross-face Nerve Graft in the Treatment of Facial ParalysisCompletedNCT03006783
25Randomized Controlled Trial of Acupuncture to Treat Bell's Palsy According to Different StagesCompletedNCT00608660
26A Clinical Study on the Combined Magnetic and Oxygen Treatment for Bell's PalsyCompletedNCT01686464
27Acupuncture With Deqi And Psychological Effects in Treatment of Bell's PalsyCompletedNCT00685789
28Prednisone-Placebo vs Prednisone-Valacyclovir in Bell´s PalsyCompletedNCT00561106
29Study of a New Technique to Improve the Symptoms of Orofacial Discomfort in Patients With Peripheral Facial ParalysisCompletedNCT01327157
30Cognitive Function and Emotional Possessing in Bilateral Facial PalsyCompletedNCT02179450
31Complications in Parotid SurgeryCompletedNCT02486393
32Post-parotidectomy Facial Paresis: Intraoperative and Postoperative FactorsCompletedNCT02527226
33Retrospective Clinical Outcome of Parotid Tumor SurgeryCompletedNCT01983176
34Clinical Research Core Dental Screening ProtocolCompletedNCT00090818
35Ultrasound Evaluation of Tongue Movements in Speech and SwallowingCompletedNCT00001167
36Popliteal Block for Postoperative Pain in Knee-ankle Soft Tissue Surgery in Cerebral PalsyCompletedNCT02507700
37Brain Reorganization Following Constraint-Induced Therapy in Children With Cerebral PalsyCompletedNCT00100503
38Botox and Suction-Curettage for Treatment of Excessive Underarm Sweating (Axillary Hyperhidrosis)CompletedNCT01274611
39Home-Based Diagnosis and Management of Sleep-Related Breathing Disorders in Spinal Cord InjuryCompletedNCT01882257
40Tactile Learning in Stroke PatientsCompletedNCT00283881
41Natural History in CCFDN and IBM SyndromesCompletedNCT01902940
42MDs on Botox Utility (MOBILITY)CompletedNCT00535938
43The Role of a Device to Evaluate the Neuromuscular Function in Assessing Muscle in Facial Paralysis PatientsRecruitingNCT02489162
44Quantification, Analysis and Simulation of Facial Mimics MovementsRecruitingNCT02002572
45R. I. S. POS. T. ARecruitingNCT01991665
46A Multicenter Study to Evaluate a Borrelia Diagnostic Test in Subjects With Early Stage or Late Stage Lyme DiseaseRecruitingNCT02741609
47Effect of DBS on Quality of Life in Dyskinetic Cerebral PalsyRecruitingNCT02097693
48Effects of Altering Handle Height of Posterior WalkersRecruitingNCT02467829
49Human Movement DatabaseRecruitingNCT00001252
500205 Esteem New Subject Enrollment Post Approval StudyRecruitingNCT02689349

Search NIH Clinical Center for Facial Paralysis

Inferred drug relations via UMLS67/NDF-RT45:


Cochrane evidence based reviews: facial paralysis

Genetic Tests for Facial Paralysis

About this section

Genetic tests related to Facial Paralysis:

id Genetic test Affiliating Genes
1 Facial Palsy26

Anatomical Context for Facial Paralysis

About this section

MalaCards organs/tissues related to Facial Paralysis:

35
Bone, Brain, Eye, Testes, Tongue, Colon, Spinal cord

Animal Models for Facial Paralysis or affiliated genes

About this section

MGI Mouse Phenotypes related to Facial Paralysis:

40
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053829.1ANKH, HOXA2, HOXB1, LRP5, NF2, TGFB1
2MP:00053889.1ANKH, GSN, HOXA2, HOXB1, NF2, TGFB1
3MP:00053798.9CADM1, CD40LG, GSN, HOXB1, LRP5, NF2
4MP:00036318.5CADM1, CD40LG, GSN, HOXA2, HOXB1, LRP5
5MP:00053848.4ANKH, CADM1, CD40LG, GSN, HOXA2, HOXB1
6MP:00053878.3ANKH, CADM1, CD40LG, GSN, HOXB1, LRP5
7MP:00053907.6ANKH, CD40LG, GSN, HOXA2, HOXB1, LRP5

Publications for Facial Paralysis

About this section

Articles related to Facial Paralysis:

(show top 50)    (show all 622)
idTitleAuthorsYear
1
Reply: Epidemiological overview of synkinesis in 353 patients with longstanding facial paralysis under treatment with botulinum toxin for 11 years. (27088841)
2016
2
Restoration of eye closure in facial paralysis using implantable electromagnetic actuator. (27642163)
2016
3
Corticosteroids for Bell's palsy (idiopathic facial paralysis). (27428352)
2016
4
Levator lengthening technique using cartilage or fascia graft for paralytic lagophthalmos in facial paralysis. (26952126)
2016
5
Antiviral treatment for Bell's palsy (idiopathic facial paralysis). (26559436)
2015
6
Recurrent facial paralysis for 12 years. (26448255)
2015
7
Lengthening temporalis myoplasty for single stage smile reconstruction in children with facial paralysis. (25254868)
2014
8
Recycle of temporal muscle in combination with free muscle transfer in the treatment of facial paralysis. (23283482)
2013
9
Facial paralysis and mediastinitis due to odontogenic infection and poor prognosis. (24220381)
2013
10
Congenital aplasia of the external ear canal and total dehiscence of mastoid-tympanic segment of the facial nerve as a cause of recurrent facial paralysis. (24220460)
2013
11
Neuro-proprioceptive facilitation in the re-education of functional problems in facial paralysis. A practical approach. (24505900)
2013
12
Facial Disfigurement: Restoration of Facial Dynamics in a Patient with Concomitant Facial Paralysis and Blindness. (24114708)
2013
13
Use of an individual mandibular advancement device for an?obstructive sleep apnoea patient with facial paralysis: a short-term follow-up case report. (22329406)
2012
14
Rehabilitation of central facial paralysis with hypoglossal-facial anastomosis. (22935815)
2012
15
Ecthyma gangrenosum in a previously healthy pediatric patient and associated facial paralysis and persistent hyperplastic primary vitreous. (23569541)
2012
16
Facial paralysis and lymphocytic facial neuritis in a rhesus macaque (Macaca mulatta) positive for simian retrovirus type D2. (22330582)
2011
17
Peripheral facial paralysis and bilateral carotid pseudoaneurysms of petrous localization: a case report. (23984216)
2011
18
Management and outcomes of facial paralysis from intratemporal blunt trauma: a systematic review. (21225812)
2010
19
Effect of delayed decompression after early steroid treatment on facial function of patients with facial paralysis. (19437165)
2010
20
Sir Charles Bell was not affected by facial paralysis himself! (20464311)
2010
21
Bilateral otitis media with facial paralysis in a Japanese black calf. (19684349)
2009
22
Outcomes of direct muscle neurotization in pediatric patients with facial paralysis. (20009835)
2009
23
Secondary surgery in adult facial paralysis reanimation. (19952647)
2009
24
Facial paralysis: research and future directions. (18470838)
2008
25
Chronic pachymeningitis and bilateral facial paralysis secondary to renal osteodystrophy. (18347262)
2008
26
Combination of hypoglossal-facial nerve jump graft by end-to-side neurorrhaphy and cross-face nerve graft for the treatment of facial paralysis. (17530609)
2007
27
Peripheral primitive neuroectodermal tumor: a rare case of peripheral facial paralysis. (17505616)
2007
28
Correction of ectropion in facial paralysis. (16462363)
2006
29
Idiopathic facial paralysis (Bell's palsy) in the immediate puerperium in a patient with mild preeclampsia: a case report. (15868184)
2005
30
Facial paralysis in Wegener's granulomatosis of the middle ear. (11276335)
2001
31
The SOOF lift as an adjunct in rehabilitation of facial paralysis: help or hype? (11460300)
2000
32
Primary facial rehabilitation in facial paralysis after extirpative surgery. (11074718)
2000
33
New eyebrow lift technique using a semiautomatic suturing device (maniceps) for patients with facial paralysis. (11128757)
2000
34
Early perioperative use of polytef suspension for the management of facial paralysis after extirpative skull base surgery. (11074717)
2000
35
Necrotizing otitis externa, otitis media, peripheral facial paralysis, and brain abscess in a thalassemic child after allogeneic BMT. (9783316)
1998
36
Iatrogenic facial paralysis prevention. (8972995)
1996
37
24 cases of facial paralysis treated by scalp acupuncture and body acupuncture. (9389121)
1996
38
Symmetry and synkinesis during rehabilitation of unilateral facial paralysis. (7674438)
1995
39
Free vascularized double muscle transplantation for the treatment of facial paralysis. (7761517)
1995
40
Long-term follow-up of nerve conduction velocity in cross-face nerve grafting for the treatment of facial paralysis. (8171133)
1994
41
Long-term results of severe facial paralysis. (10774436)
1994
42
Anti-Borrelia burgdorferi antibodies in sera of patients with facial paralysis. (10774421)
1994
43
Postdenervation muscular changes in facial paralysis. (10774306)
1994
44
MAcniA"re's attacks associated with facial paralysis. (8217743)
1993
45
Comments regarding prognostic significance of stapes reflex in Bell's palsy, application of electroneuronography in managing Bell's palsy, and tuberculosis of the middle ear in facial paralysis, management of an injured facial nerve following middle ear surgery. (1805644)
1991
46
Anotia, facial paralysis, and heart disease. (3973798)
1985
47
PAROTITIS AND FACIAL PARALYSIS IN MID-LINE GRANULOMA. (14256342)
1965
48
Bilateral facial paralysis and abducens palsy; two cases. (18225098)
1948
49
Superior petrosal and cavernous sinus thrombosis and basal petrositis; observed as complication of destructive labyrinthitis with facial paralysis. (20284480)
1947
50
The Association of Optic Neuritis, Facial Paralysis, and Facial Hemiatrophy. (16693016)
1934

Variations for Facial Paralysis

About this section

Expression for genes affiliated with Facial Paralysis

About this section
Search GEO for disease gene expression data for Facial Paralysis.

Pathways for genes affiliated with Facial Paralysis

About this section

Pathways related to Facial Paralysis according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
19.6GSN, LRP5

GO Terms for genes affiliated with Facial Paralysis

About this section

Cellular components related to Facial Paralysis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1cortical actin cytoskeletonGO:00308649.7GSN, NF2

Biological processes related to Facial Paralysis according to GeneCards Suite gene sharing:

(show all 8)
idNameGO IDScoreTop Affiliating Genes
1negative regulation of DNA replicationGO:000815610.2NF2, TGFB1
2oligodendrocyte developmentGO:001400310.2GSN, TGFB1
3negative regulation of cell-cell adhesionGO:002240810.1NF2, TGFB1
4negative regulation of osteoblast differentiationGO:00456689.9HOXA2, LRP5
5lens fiber cell differentiationGO:00703069.9NF2, TGFB1
6osteoblast developmentGO:00020769.9HOXA2, LRP5
7cell-cell junction organizationGO:00452169.7NF2, TGFB1
8anterior/posterior pattern specificationGO:00099529.4HOXA2, HOXB1, LRP5

Sources for Facial Paralysis

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
26GTR
27HGMD
28HMDB
29ICD10
30ICD10 via Orphanet
31ICD9CM
32IUPHAR
33KEGG
36MedGen
38MeSH
39MESH via Orphanet
40MGI
43NCI
44NCIt
45NDF-RT
48NINDS
49Novoseek
51OMIM
52OMIM via Orphanet
56PubMed
57QIAGEN
62SNOMED-CT via Orphanet
66Tumor Gene Family of Databases
67UMLS
68UMLS via Orphanet